# EDGAR Filing Document

**Accession Number:** 0000884624
**File Stem:** 0001193125-26-266679
**Filing Date:** 2026-6
**Character Count:** 9133
**Document Hash:** 465fa1dab2f82a8e630e9b1d73a3bca6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-266679.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001193125-26-266679

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Orthofix Medical Inc.
- **CENTRAL INDEX KEY:** 0000884624
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1223

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19961
- **FILM NUMBER:** 261081419

**BUSINESS ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056
- **BUSINESS PHONE:** 214-937-2000

**MAIL ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORTHOFIX INTERNATIONAL N V
- **DATE OF NAME CHANGE:** 19970708

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 11, 2026<br>

------

ORTHOFIX MEDICAL INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-19961 | 98-1340767 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 3451 Plano Parkway |  |  |
| Lewisville**,** Texas |  | 75056 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (214) 937-2000<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common stock, $0.10 par value per share | OFIX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.**

 *Approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan*

On June 10, 2026, Orthofix Medical Inc. (the "<u>Company</u>") held its 2026 Annual Meeting of Shareholders (the "<u>Annual Meeting</u>"). At the Annual Meeting, the Company's shareholders approved Amendment No. 5 (the "<u>SPP Amendment</u>") to the Company's Second Amended and Restated Stock Purchase Plan (as previously amended, the "<u>SPP</u>"). The Company's named executive officers are participants in the SPP. The SPP Amendment increases the number of shares of the Company's common stock available for issuance under the SPP by 1,250,000 shares. The SPP Amendment does not provide for any other changes to the SPP. The text of the SPP Amendment is filed herewith as Exhibit 10.1 and incorporated herein by reference. The text of the SPP and the SPP Amendment are also set forth as [<u>Appendix A</u>](https://www.sec.gov/Archives/edgar/data/884624/000119312526191716/ofix-20260429.htm#appendix_a) to the Company's proxy statement for the Annual Meeting, and the terms of the SPP and the SPP Amendment are further described in [<u>pages 73-75 of such proxy statement</u>](https://www.sec.gov/Archives/edgar/data/884624/000119312526191716/ofix-20260429.htm#proposal_4)for the Annual Meeting.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 10, 2026, the Company held the Annual Meeting. The total number of common shares eligible to vote as of the record date, April 13, 2026, was 40,385,869 and, pursuant to the Company's Bylaws, 20,192,935 shares were required to be present or represented at the Annual Meeting to constitute a quorum. The total number of common shares present or represented at the Annual Meeting was 34,776,676, and a quorum therefore existed. Of the shares present and represented, 4,704,457 constituted broker non-votes for purposes of items 1, 2 and 4 below.

At the Annual Meeting:

1. *Election of Board of Directors.* The following persons were elected as directors of the Company for a one-year term expiring at the 2027 Annual Meeting of Shareholders:

---

| | | | |
|:---|:---|:---|:---|
| *Name* | *Votes For* | *Votes Against* | *Abstentions* |
| Alan L. Bazaar | 29026559 | 1014417 | 31243 |
| Wayne Burris | 24898636 | 5162812 | 10771 |
| Massimo Calafiore | 29344227 | 725358 | 2634 |
| Vickie L. Capps | 29373109 | 667919 | 31191 |
| Michael M. Finegan | 29238156 | 827899 | 6164 |
| Jason M. Hannon | 29389134 | 676817 | 6268 |
| John B. Henneman, III | 28798930 | 1262304 | 10985 |
| Charles R. Kummeth | 28990854 | 1070316 | 11049 |
| Shweta S. Maniar | 29631030 | 434784 | 6405 |
| Michael E. Paolucci | 24698858 | 5367249 | 6112 |

---

2. *Advisory and Non-Binding Resolution to Approve Executive Compensation.* The advisory and non-binding resolution to approve executive compensation was approved by a vote of (i) 24,480,474 in favor, (ii) 5,577,200 against, and (iii) 14,545 abstaining.

3. *Ratification of the Selection of Ernst & Young LLP.* The selection of Ernst & Young LLP to act as the independent registered public accounting firm for the Company and its subsidiaries for the fiscal year ending December 31, 2026 was ratified by a vote of (i) 33,262,505 in favor, (ii) 1,384,292 against, and (iii) 129,879 abstaining.

4. *Approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan.* Shareholders approved Amendment No. 5 to the Company's Second Amended and Restated Stock Purchase Plan by a vote of (i) 29,235,005 in favor, (ii) 831,625 against, and (iii) 5,589 abstaining.

------

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| *Exhibit No.* | *Description* |
| 10.1 | [<u>Amendment No. 5 to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan</u>](ofix-ex10_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Orthofix Medical Inc. |
| Date: | June 11, 2026 | By:  | /s/ J. Andrés Cedrón |
|  |  |  | J. Andrés Cedrón<br>Chief Legal Officer |

---

------

## Exhibit 10.1

Exhibit 10.1

**AMENDMENT NO. 5 TO**

**ORTHOFIX MEDICAL INC.**

**SECOND AMENDED AND RESTATED<br>STOCK PURCHASE PLAN**

The Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan (as amended to date, the "Plan") is hereby amended as follows:

Section 3(a) of the Plan is amended and restated in its entirety to read in full as follows:

"The total number of shares of Orthofix Stock reserved and available for issuance pursuant to the Plan shall not exceed 6,100,000 shares. The shares of Orthofix Stock purchasable pursuant to the Plan may be authorized but previously unissued shares of Orthofix Stock or shares of Orthofix Stock held in treasury or purchased in the open market or in privately negotiated transactions. The Company shall bear all costs in connection with issuance or transfer of any shares and all commissions, fees and other charges incurred in purchasing shares for distribution pursuant to the Plan."

------